Cortical Labs

Cortical Labs occupies an unusual position between biotechnology, neuroscience, semiconductor hardware and AI infrastructure. Its core differentiation is not a faster conventional accelerator, but the use of living human neurons connected to silicon and controlled through software. The CL1, Cortical Cloud and Cortical Labs API give the company a route to serve researchers and developers without requiring every user to build a specialized biological laboratory. That model distinguishes it from conventional AI infrastructure providers, whose systems rely on digital processors, and from neuromorphic hardware companies that emulate neural behavior with silicon rather than living cells. The company’s categories also place it adjacent to neuroscience research-tool vendors and robotics platforms, where biological learning could be evaluated in practical environments. Its $10.99 million in recorded funding and eight-investor base suggest an early commercial stage rather than established infrastructure scale. The competitive question is therefore whether biological systems can deliver measurable advantages in energy use, adaptability or drug and medical research that justify their operational complexity, maintenance requirements and ethical constraints.

Cortical Labs’ trajectory shows a progression from research demonstration to commercial product and then to infrastructure experimentation. Founded on Jun 1, 2019, the company raised a $1 million Seed round in 2019 and a further $9,988,959 Seed round announced on Apr 19, 2023, led by Horizons Ventures. It launched the CL1 in March 2025 as a code-deployable biological computer and later promoted units priced at $35,000, creating an initial hardware commercialization path. In February 2026, CL1 was demonstrated running Doom, while June coverage described approximately 200,000 human neurons participating in biological computing experiments. The Mar 4, 2026 Venture Round, led by 3C AGI Partners and Horizons Ventures, marks the latest financing inflection point, although its amount is undisclosed. Product expansion into Cortical Cloud and an API indicates an effort to make the platform accessible beyond laboratories and individual CL1 installations. The August 2026 biological data-centre prototype in Singapore represents the largest strategic expansion described publicly: it tests whether the technology can move from research and demonstrations into operational computing infrastructure. Hiring remains active through careers and internship opportunities, but available staffing data still places the company in the 1–10 employee range, leaving execution capacity and growth rate difficult to quantify.